A Phase 3 interventional study of Baricitinib in Juvenile Idiopathic Arthritis, sponsored by Eli Lilly and Company. Recruiting at 77 sites in 20 countries. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Arthritis, Juvenile with a site in Japan — 3 open to participants now, 6 under way, 5 of them phase 3. Arthritis, Juvenile · Japan.
Among the 12 studies in Arthritis, Juvenile with a site in Japan, this one is the 3rd largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2019, is one of 10 in phase 3, and was the 6th registered.
366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.
Browse Arthritis, Juvenile studies →3 of the 12 studies in Arthritis, Juvenile with a site in Japan are open now. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in Japan, United States, Argentina and 15 more countries
Ages 3+
AbbVie · Sites in Japan, United States, Argentina and 14 more countries
Ages 1–17
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.
This study: 1 Year to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 190 is above the median of 52 across 231 interventional studies indexed under Arthritis, Juvenile.
Median enrollment 58 across the 11 interventional studies, 113 across the 1 observational. Of the 6 that completed or were terminated, 6 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 8 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 4 studies filed under Arthritis, Juvenile — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Arthritis, Juvenile with a site in Japan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Baricitinib given orally.
Drug: Baricitinib
Administered orally.
Also known as: LY3009104
Number of Participants with One or More Serious Adverse Event(s) (SAEs)
Number of participants with one or more SAEs
Time frame: Baseline through Week 264
Number of Participants with Permanent Investigational Product Discontinuations
Number of participants with permanent investigational product discontinuations
Time frame: Baseline through Week 264
Proportion of Participants Achieving Pediatric American College of Rheumatology 30 Responder Index (PedACR30)
Proportion of participants achieving PedACR30
Time frame: Week 264
Proportion of Participants who have Disease Flare
Proportion of participants who have disease flare
Time frame: Baseline through Week 264
Proportion of Participants with Inactive Disease
Proportion of participants with inactive disease
Time frame: Week 264
Proportion of Participants with Minimal Disease Activity
Proportion of participants with minimal disease activity
Time frame: Week 264
Proportion of Participants in Remission
Proportion of participants in remission
Time frame: Week 264
Change from Baseline in Juvenile Arthritis Disease Activity Score-27 (JADAS27)
Change from baseline of originating study in JADAS27
Time frame: Baseline, Week 264
Change from Baseline in Arthritis-Related Pain Severity as Measured by the Childhood Health Assessment Questionnaire (CHAQ) Pain Visual Analog Scale (VAS) Item
Change from baseline in arthritis-related pain severity as measured by the CHAQ pain VAS item
Time frame: Baseline, Week 264
Change from Baseline in Psoriasis Area and Severity Index (PASI)
Change from baseline in PASI
Time frame: Baseline, Week 264
Change from Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index
Change from baseline in SPARCC enthesitis index
Time frame: Baseline, Week 264
Change from Baseline in Juvenile Spondyloarthritis Disease Activity Index (JSpADA)
Change from baseline in JSpADA
Time frame: Baseline, Week 264
Change from Baseline in Immunoglobulin Levels
Change from baseline in immunoglobulin levels
Time frame: Baseline, Week 264
Change from Baseline in Immunophenotyping (T Cells)
Change from baseline in immunophenotyping (T Cells)
Time frame: Baseline, Week 264
Change of Immunoglobulin G (IgG) Titers
Change of IgG titers
Time frame: Pre-Vaccination to 12 Weeks Post-Vaccination
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · www.clinicalstudydatarequest.com
Started Apr 2019 (actual). Primary completion is estimated for Jul 2031, 147 months after the start.
Of 36 phase 3 interventional studies under Arthritis, Juvenile, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's planned 147 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baricitinib